Treatment strategies are tailored based on the patient's age, overall health, and the severity of the condition.

1. Blood Transfusions: While not curative, blood transfusions are pivotal in managing symptoms and preventing complications:

Red Blood Cell Transfusions: These elevate haemoglobin levels, alleviating anaemia-related fatigue and weakness.

Platelet Transfusions: These are essential to prevent excessive bleeding in patients with low platelet counts.

Repeated transfusions can lead to iron overload, potentially harming vital organs. Chelation therapy may be employed to remove excess iron. Additionally, the development of antibodies against transfused blood cells can reduce transfusion efficacy over time. Immunosuppressive medications can mitigate this risk.

2. Haematopoietic Stem Cell Transplantation (HSCT)

For eligible patients, HSCT offers a potential cure:

Procedure: The patient's defective bone marrow is eradicated using chemotherapy or radiation. Subsequently, healthy stem cells from a compatible donor are infused, migrating to the bone marrow to regenerate blood cells.

Eligibility: Ideal candidates are younger patients with a matched sibling donor. However, suitable donors are not always available, and the procedure carries risks such as graft-versus-host disease and infections.

3. Immunosuppressive Therapy

For patients ineligible for HSCT or when autoimmune mechanisms are implicated:

Medications: Agents like anti-thymocyte globulin (ATG) and cyclosporine suppress immune activity against bone marrow cells. These are often used in combination to enhance efficacy.

Considerations: While effective, these therapies can further weaken the immune system, increasing infection susceptibility. Relapses can occur upon discontinuation.

4. Bone Marrow Stimulants

To encourage bone marrow activity:

Growth Factors: Drugs such as sargramostim (Leukine), filgrastim (Neupogen), and pegfilgrastim (Neulasta) stimulate white blood cell production.

Thrombopoietin Receptor Agonists: Medications like eltrombopag (Promacta) and hetrombopag (Hengqu) promote platelet production and have shown promise in restoring blood cell counts in some patients.

5. Infection Management

Due to compromised immunity:

Preventive Measures: Prophylactic antibiotics and antivirals may be prescribed to avert infections.

Prompt Treatment: Early intervention at the first sign of infection is crucial to prevent severe complications.

6. Addressing Underlying Causes

If aplastic anaemia results from external factors:

Drug-Induced Cases: Discontinuing the offending agent often leads to improvement.

Pregnancy-Related Cases: The condition may resolve post-delivery; however, treatment is necessary if it persists.

Each treatment option carries specific risks and benefits. A comprehensive evaluation by a haematologist is essential to devising an individualised treatment plan.

Severe Aplastic Anaemia